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Abstract
Introduction—Chimeric antigen receptors (CARs) usually combine the antigen binding site of a
monoclonal antibody with the signal activating machinery of a T cell, freeing antigen recognition
from major histocompatibility complex restriction and thus breaking one of the barriers to more
widespread application of cellular therapy. Similar to treatment strategies employing monoclonal
antibodies, T cells expressing CARs are highly targeted, but additionally offer the potential
benefits of active trafficking to tumor sites, in vivo expansion and long term persistence.
Furthermore, gene transfer allows the introduction of countermeasures to tumor immune evasion
and of safety mechanisms.
Areas covered—The authors review the basic structure of so-called first and later generation
CARs and their potential advantages over other immune therapy systems. It is described how these
molecules can be grafted into immune cells (including retroviral and non-retroviral transduction
methods) and strategies to improve the in vivo persistence and function of immune cells
expressing CARs are discussed. Examples of tumor associated antigens that have been targeted in
preclinical models are presented and clinical experience with these modified cells is summarized.
Finally, a discussion on safety issues surrounding CAR gene transfer into T cells and potential
solutions to them, are presented.
Expert opinion—Because of recent advances in immunology, genetics and cell processing,
CAR-modified T cells will likely play an increasing role in the cellular therapy of cancer, chronic
infections and autoimmune disorders.
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1. Introduction
Allogeneic hematopoetic stem cell transplantation is probably the first example of a cellular
therapy exploiting an antitumor immune response, although this effect remained largely
unappreciated until follow-up studies demonstrated decreased relapse rates of allogeneic
versus syngeneic transplants.1 The recognition of a graft-versus-tumor effect led to the
development of strategies using donor lymphocyte infusion (DLI) after transplantation,
which were successful against relapsed chronic myelogenous leukemia2 and Epstein-Barr
Virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD).3 The high
incidence of severe graft-versus-host-disease (GVHD) after DLI sparked the development of
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approaches to minimize that risk by ex vivo selecting and expanding virus-specific T cells,
which proved very effective.4 For example, in vitro expanded, donor-derived EBV-specific
cytotoxic T lymphocytes (CTLs) have been safely administered, or adoptively transferred, to
numerous patients and shown to proliferate in vivo, persist for more than a decade and
localize to sites of EBV-associated tumors. No disease has been detected in more than one
hundred patients at high risk of developing EBV-PTLD who received CTL prophylaxis
(versus 12% of controls), and complete and sustained resolution of these tumors has been
observed in 11 out of 13 patients with resistant lymphoma.5
In contrast to tumor-associated viral antigens, which have been successfully targeted by in
vitro selected T cells, most other tumor-associated antigens (TAAs) have proved more
challenging, a fact no doubt related to most known TAAs being endogenous and thus more
likely to evoke tolerance.6, 7 One approach to obtain consistent manufacture of T cells
reactive against weakly immunogenic TAAs has been the expression of transgenic T cell
receptors (TCR) in lymphocytes. While some efforts have focused on expressing rare,
naturally occurring, self- or allo-reactive, tumor-specific TCRs in T cells,8 many groups
have developed instead artificial receptors that are engineered to bind specifically to TAAs.
These receptors couple a major histocompatibility complex (MHC)-unrestricted interaction
between a TAA and its recognizing molecule to the activating signal machinery of T cells
and, because they combine portions of different molecules, they are usually referred to as
chimeric antigen receptors (CARs). Here, we will review the basic structure of CARs and
their potential advantages over other systems. We will describe at length how these
molecules can be grafted into immune cells, discuss issues related to improving their
persistence and function in vivo, and give examples of antigens that have been targeted. We
will finish with a discussion on safety issues surrounding CAR gene transfer into T cells and
potential solutions for these problems.
2. CARs
2.1. Basic structure
A CAR combines the binding site of a molecule that attaches strongly to the antigen being
targeted (i.e., a “binding portion”) with the cytoplasmic domains of conventional immune
receptors responsible for initiating signal transduction that leads to lymphocyte activation
(the “signaling portion”).9–12 Most commonly, the binding portion used is derived from the
structure of the Fab (antigen binding) fragment of a monoclonal antibody (mAb) that has
high affinity for the antigen being targeted (Fig. 1). Because the Fab is the product of two
genes, the corresponding sequences are usually combined via a short linker fragment that
allows the heavy-chain to fold over the light-chain derived peptides into their native
configuration, creating a single-chain fragment variable (scFv) region.13, 14 As many of the
original CARs systems attached an antibody fragment to a T cell, they were also called “T-
bodies”.15 Other possible antigen binding moieties include signaling portions of hormone or
cytokine molecules,16, 17 the extracellular domains of membrane receptors18 and peptides
derived from screening of libraries (e.g. phage display).19, 20
Since some degree of flexibility between the binding and the signaling portions of the CAR
may be desirable and because projection of the antigen recognition domains away from cell
surface may be required for better binding to the antigen, a hinge region bridging the
binding and signaling portions is generally included in the construct. Examples include the
CH2CH3 portion of an immunoglobulin molecule such as IgG1. The importance of the hinge
region is illustrated by studies which demonstrated that, for the same targeting construct,
optimal T cell activation depends on the relative length of this spacer region and the distance
of the epitope from the target cell membrane.21–24 For instance, juxtamembrane epitopes
require in general longer spacer regions than those farther away from the membrane.
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The signaling portion of CARs contains usually the intracellular domains of the zeta (ζ)
chain of the TCR/CD3 complex25 or, less commonly, of the gamma (γ) chain of the
immunoglobulin receptor FcεRI26, 27 or the CD3-epsilon (ε) chain,28 with the
transmembrane region being derived from the same molecules or other type I
transmembrane proteins such as CD4, CD8 or CD28.
2.2. Advantages and disadvantages of using CARs
Similar to treatment strategies employing monoclonal antibodies, T cells expressing
transgenic native TCRs or CARs are highly targeted, but additionally offer the potential
benefits of active trafficking to tumor sites, in vivo expansion and long term persistence.
Furthermore, gene transfer allows the introduction of countermeasures to tumor immune
evasion and of safety mechanisms. Compared to transgenic native TCRs, though, chimeric
antigen receptors have human leukocyte antigen (HLA)-unrestricted activity and can target
non-protein antigens (Table I). This is important as many tumors adopt immune evasion
strategies affecting MHC processing and presentation,29–32 and several TAA are
carbohydrates or glycolipids. Additionally, because CARs are single molecules that do not,
in principle, interact with either of the native TCR chains, they are not subject to mispairing
with complementary chains, a problem that can occur when four (two native and two
transgenic) TCR chains are expressed in the same lymphocyte: unless the two native TCR
chains are selectively ablated, pairing of a native chain with a transgenic chain can lead to
decreased antigen recognition through the transgenic receptor and, even worse, off-target
effects if an unwanted specificity happens to be created. This has been recently documented
in vitro33 and in a murine model,34 in which mixed TCRs (formed from pairing of one
endogenous and one exogenous chain) were shown to drive autoreactivity. In the latter
study, a syndrome resembling transfusion-associated GVHD was observed, the
manifestations of which could be ameliorated by the use of systems that reduced pairing of
endogenous and exogenous TCR chains. After publication of these studies, however, it was
noted that no such complications have been observed after infusion of transgenic TCR-
modified T cells in more than 100 human subjects.35
Nonetheless, a limitation of CARs not relying on antigen processing is that only surface
antigens can be recognized by them. Also, the presence of soluble antigen shed by tumors
could compete with binding to and killing of the malignant cells,15 although at least in the
settings investigated so far this seems not to be a major issue. In vitro studies have shown
that anti-CEA CARs are not inhibited by soluble CEA, even at high concentrations.28, 36, 37
2.3. First and later generation CARs
The initially published CARs were designed with a single signaling domain.9–12 Several
studies employing T cells modified with these so-called first generation CARs established
the feasibility of the approach, but showed very limited clinical benefit.38–41 This has been
primarily thought to be due to ineffective or incomplete activation of these cells, leading to a
very limited persistence, compared for instance with that of EBV-specific CTLs, which have
been detected in circulation up to 15 years after infusion.5
To exert its function, a T cell requires binding through its TCR to its cognate (native)
antigen presented by an HLA molecule (resulting in the so-called “signal 1”). So as to
become fully activated, however, a naïve T cell requires additional stimulatory events
prompted by neighboring cells. Otherwise, the end result of stimulation through the TCR is
T cell apoptosis or anergy. Many of these additionally required pathways have been
described, including activating ligands displayed on the surface of the cells presenting the
antigen, which bind costimulatory molecules in T cells (leading to the generation of a
“signal 2”), and stimulatory cytokines secreted by the same or other nearby cells (sometimes
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referred to as “signal 3”).42 Examples of these ligands include CD80 and CD86, normally
present in activated antigen presenting cells, which bind the costimulatory CD28 receptor,
expressed by T cells.
As tumor cells often lack expression of the costimulatory ligands involved in physiologic
activation of T cells,6 this has been assumed to be the basis for the modest activation,
expansion and persistence of T cells expressing first generation CARs. Additionally, the
prolonged expansion period of T cells in vitro may also be associated with downregulation
of the receptors for those costimulatory ligands, further compounding the problem.
So as to provide T cells with additional activating signals, more recently developed second
generation CARs have been engineered to include another stimulatory domain, usually
derived from the intracytoplasmatic portion of costimulatory molecules, such as CD28 (Fig.
2), CD134/OX40, CD137/4-1BB, Lck, ICOS and DAP10.43–51 As these costimulatory
domains are incorporated in the CAR, its activation by engagement with the respective
antigen delivers both signal 1 and signal 2 to T cells, bypassing the need for costimulatory
ligands and preventing potential anergy or apoptosis resulting from a solitary signal 1. Many
in vitro and preclinical studies comparing first and second generation CARs demonstrate
improved function of T cells bearing the latter.43–51 Third generation CARs incorporating 3
or more stimulatory domains have also been described,24, 48, 52 but it is unclear whether the
strong costimulation potentially obtained will always be advantageous.53
3. Grafting CARs into immune cells
3.1. Gene transfer methods
Although it is possible to transiently express CARs in T cells by transfecting them with
naked DNA plasmids or mRNA (for instance, to quickly and reversibly test them for
toxicity), in most instances the goal is to obtain constitutive expression of the CAR. As such,
techniques that achieve permanent genetic modification of T cells are usually employed.54
The most frequently used strategy uses gammaretroviruses or lentiviruses (both members of
the retrovirus family) that are engineered to encode the full length CAR molecule. Upon
infection of the target cells, the viral genomic RNA gets retrotranscribed by the virus reverse
transcriptase into DNA, which in turn gets randomly inserted into the host cell DNA through
the action of a viral integrase, thus becoming part of that cell’s genome.55 Because they lack
key genes (including gag, pol and env) the retroviruses used are replication-defective,
meaning that they are unable to complete their life cycle by proliferating and infecting other
cells.56 The probability of generating replication competent retroviruses (RCR) during their
mass production or spontaneously after target cell infection is very low, but ruling out these
events are part of the quality assurance and quality control processes that are required during
manufacture of the CAR-expressing T cells employing these manufacturing methods.57
In contrast to lentiviruses, which are capable of infecting resting cells, gammaretroviruses
require that their target cells are dividing for successful integration.58 Because peripheral
blood lymphocytes, the usual starting population, are not actively cycling, they need to be
activated in vitro before they can be successfully transduced by gammaretroviruses (in fact,
even lentiviruses integrate better into dividing than resting cells).
Two methods can be employed to obtain a population of activated T cells. Most commonly,
polyclonal stimulation of T cells is obtained by using an activating monoclonal antibody
anti-CD3 (OKT3). The “lymphoblasts” (OKT3-blasts) thus obtained are easily transducible
by retroviruses (Fig. 3). Concomitant stimulation of native CD28 receptors by another
agonistic monoclonal antibody facilitates T cell activation further. After stimulation and
transduction, which takes approximately 48 hours, the T cells are kept in culture for 2 to 3
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weeks in IL-2 containing medium until sufficient numbers for clinical application are
reached.59 Alternatively, T cells with particular specificities can be selectively expanded in
the presence of antigen presenting cells (APCs), such as dendritic cells or lymphoblastoid
cell lines (LCL).60 As antigen recognition and interaction with APCs drives activation of T
cells, these antigen-specific T cells can then be transduced with a retrovirus encoding a
CAR, generating bispecific cell lines, which may have some advantages over OKT3-
activated lines (discussed below).
Because retroviral production under good manufacturing practices (GMP) is expensive,
some groups have adopted non-viral methods for permanent transduction, specifically
transposon-based systems, including Sleeping Beauty61 and PiggyBac.62 These usually
require double transfection with one plasmid containing the expression cassette for the
desired CAR and another encoding a transposase. Once expressed in the target cells, the
transposase catalyzes the integration of the CAR gene into specific, though pretty much
randomly distributed, sites throughout the genome. The reaction is essentially irreversible
and thus leads to stable integration of the gene of interest.
Selection of a particular transduction method depends on its potential advantages and
disadvantages and also on each center’s experience and logistics. Retroviral transduction is
very efficient, minimizing the time to achieve clinically useful cell numbers. However, as
noted above, it is an expensive method, there is a potential concern of generating replication
competent retrovirus (although this has never been observed in any trial so far), and viral
genes may be immunogenic, curtailing survival of the transduced cells. Earlier non-viral
methods relied on electroporation of cells with a naked DNA plasmid encoding the CAR
and its illegitimate recombination for stable genomic integration.63 The efficacy of this
procedure is low and requires long cell culture periods to allow selection of T cells with
stable integrants, during which cells may become terminally differentiated or senescent. The
newer non-viral methods described above are more effective and may circumvent some of
these issues, but they have not been directly compared to retroviral transduction.
Depending on the final application and the overall efficacy of the transduction method, a
selectable marker (such a surface antigen or an antibiotic resistance gene) can be used to
facilitate purification of the transduced cells. This is especially important when the
transduction is done using methods that have lower success rates.63 On the other hand,
because some selectable markers may be immunogenic and compromise survival of the
transduced cells in vivo, alternative selection methods have been proposed. One such
approach engineers T cells to express a cytokine receptor, such as that for IL-4, in cis with
the CAR.64 After T-cell transduction, if the resulting cellular product is grown in the
presence of that cytokine, those cells successfully expressing the transgenic cassette will
expand preferentially over the untransduced cells. In addition, administration of that
cytokine after adoptive transfer of the modified T cells may selectively support their growth
in vivo, although their behavior in this setting is currently unknown.
3.2. Populations transduced
Most studies have focused on the genetic modification of the most abundant of the
lymphocytes subsets, i.e. αβ-TCR+ T cells, in particular, CD8+ cells, as these are thought to
be the immediate effectors of tumor cell destruction after CAR engagement. Unless PBMCs
are fractionated prior to gene transduction, however, CD4+ cells are also activated and
included in the CAR-transduced population. This is usually not a problem, as no additional
toxicity has been described for CD4+ CAR+ T-cells and because these cells may provide
help for CD8+ CAR+ T cells in vivo or have themselves significant cytotoxic activity.44, 65
Indeed, several publications have highlighted the synergistic effects of CAR-bearing CD8+
and CD4+ T cells in murine models, including HER266 and CD19-specific67 CARs.
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As the gene transfer procedures are not specific for T cells, other populations of immune
cells, which may offer specific advantages, can also be transduced using the same methods.
For instance, natural killer (NK) cells have intrinsic lytic potential and some CARs have
been engineered to contain predominantly NK-activating endodomains. This, combined with
new NK cell expansion systems, is a possible alternative to T cells.68 Moreover, another
population with endogenous killing ability, γδ-TCR+ T cells, can be easily expanded in vitro
with bisphosphonates and is amenable to transduction with a CAR.69 One advantage of this
system is that bisphosphonates are drugs that have been approved for other medical uses and
are routinely used in the treatment of patients with cancer.70 Whether any of these
populations is more effective at tumor killing is unclear at this point.
Finally, while most often the aim of CAR-modified T-cell therapy is to trigger immune
responses against endogenous TAA, there is also interest in using this approach to dampen
immune responses to endogenous antigens by transducing populations of T cells whose
primary function is to inhibit immune responses, such as regulatory T cells. The rationale in
this setting is that engagement of a CAR expressed by a regulatory T cell will trigger their
immunosuppressive machinery and thus limit or prevent immune responses against tissues
expressing the targeted antigen.71 If successful, this approach could be used in the
management of autoimmune disorders.
4. Expansion and persistence in vivo of CAR-expressing cells
Although many CAR constructs have been shown to be effective in vitro and in animal
models at mediating killing of their target cells, few clinical studies have shown consistent
anti-tumor effects. This limitation is thought to be in part, at least for trials employing first
generation CARs, due to the fact that tumor cell engagement of the CAR alone fails to
sustain sufficient T-cell growth and activation for tumor eradication. T cells require multiple
additional, or costimulatory, signals to produce optimum activation, proliferation and
survival following antigen receptor engagement.72 As discussed above, incorporating one or
more endodomains from the required costimulatory molecules into the CAR itself can
enhance T cell performance following chimeric receptor engagement. However, even T cells
expressing second generation CARs have been observed to have limited persistence in vivo
after infusion in patients, highlighting the need to find alternative methods of optimizing
their expansion after adoptive transfer.
4.1. Bispecific cells
Under normal conditions, costimulation occurs in a temporo-spatially coordinated manner,72
which may not be fully replicated within the T cells when the CAR simultaneously
generates costimulatory signals after antigen engagement, as is the case with later generation
CARs. An alternative to achieve a more physiological solution to this problem has been to
graft the CAR into virus specific CTLs40, 73–76 instead of a non-specifically, polyclonally
activated T cell population. CTLs with native receptor (αβ-TCR) specificity directed to
persistent human viruses, such as Epstein-Barr virus (EBV) or cytomegalovirus (CMV),
should receive physiological costimulation in vivo during their encounters with persistent
viral antigens on professional APCs.77 As such CTLs divide and persist in vivo for many
years following infusion,4, 5 if they are modified to coexpress a CAR directed at a TAA,
they too should obtain physiologic costimulatory signals following engagement of their
native receptors, which should in turn enhance their survival and their CAR-mediated anti-
tumor activity (Fig. 4). This hypothesis has obtained preliminary support in patients
receiving first generation CTLs expressing a CAR directed to the GD2 antigen on
neuroblastoma (summarized in section 6.1).40 In any case, the levels of expansion observed
appear lower than those expected for untransduced virus-specific T cells, which have been
seen to persist for several years.5 Potential reasons for this finding include adverse effects of
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the retroviral transduction on the physiology of the T cells and the lack of lymphodepletion
prior to adoptive transfer of these cells in this particular trial.
Whether the physiological co-stimulation received by expressing a first generation CAR
directed against a tumor-associated antigen in virus-specific CTLs will be of greater
functional benefit in vivo than the incorporation of other costimulatory endodomains (such
as CD28) into the same CAR and expressing it in OKT3-blasts is the object of ongoing
clinical trials, including a comparison between EBV-specific CTLs carrying a first
generation CD19-specific CAR and OKT3-activated T cells bearing a second generation
CAR (differing only by the inclusion of a CD28 endodomain) to treat subjects with
advanced B-cell malignancies (ClinicalTrials.gov Identifier NCT00709033).
4.2. Memory populations
The result of a physiologic immune response to a foreign antigen is a heterogenous
population of cells that play different roles. In particular, a fraction of the cells involved
becomes long-lived and is responsible for establishing immunologic memory against the
antigen that triggered that response.78 The mechanisms involved in segregating this
primarily memory population, akin to a stem cell compartment, from the rest of the immune
effectors are incompletely understood, but it is unlikely that polyclonal activation of
circulating T cells via the CD3 and CD28 receptors would be able to reproduce the hierarchy
of immune cells that is generated during native immune responses. As a consequence, it is
possible that most cells that are transduced ex vivo with CARs have mainly effector or
effector memory properties but lack memory potential. This offers an alternative explanation
for the limited persistence of CAR T cells observed in vivo so far: although, as proven by a
plethora of in vitro experiments, these cells are effective at killing targets, they may not able
to expand and persist as a memory population. In addition, this could also account for why
bispecific cells may have improved persistence in vivo: in a way, expanding and selecting
cells in the presence of APCs (the first step in the generation of bispecific cells) likely
enlists more physiologic pathways that those achieved by TCR activation outside of an
immune synapse.
While we know little about how immune memory is generated, it is commonly accepted that
different subsets of circulating T cells, identifiable by distinct surface antigen expression,
represent separate compartments of this immune memory hierarchy. For instance, antigen-
experienced T cells (i.e. memory cells) can be further divided into central memory and
effector memory cells, which differ in functional and homing properties.79 Recently, it has
been demonstrated, in a primate model, that adoptively transferred T cells derived from
central memory cells sorted from an otherwise homogenous population of T cells are able to
persist and give rise to effector cells in vivo longer than a comparable T cell population
generated from effector memory T cells.80
Understanding the factors involved in generating and maintaining a memory population,
with increased intrinsic replicative potential and self-renewal ability, would thus have
tremendous implications for our ability to establish long lasting CAR-modified cell lines. On
the other hand, this information would also give us full control to generate a population with
a limited lifespan, if a transient effect is being deliberately sought.
4.3. Avoiding immune response against transduced cells
One of the potential problems of using an artificial CAR, especially, as it is often the case,
when the new molecule contains portions derived from another species, is that the
recipient’s immune system may react against the new protein and eliminate the CAR-
bearing cells. Humanized CARs, in which the xenotypic sequences of the variable regions
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are replaced by their human homologues, have been designed and proposed as a measure to
limit immune mediated destruction of the modified cells.28, 48 Evidence for immune
recognition of CARs has been recently provided,38, 81 with studies showing generation of
cellular and humoral responses against retroviral vector, selection gene (neomycin
phosphotransferase) and CAR epitopes, underscoring the need to attenuate the
immunogenicity of both transgenes and vectors in this setting.
While immune destruction of CAR-bearing T cells could provide another explanation for the
limited persistence of T cells, many patients treated with CAR-T cells have received
significantly immunosuppressive therapy quite close to receiving those cells (especially true
in the management of hematological malignancies) and thus they may be less likely to
mount an immune response against the infused cells. Supporting the idea that immune
rejection may not be important in all settings is the fact that re-expansion of CAR-T cells
has been observed after a second infusion of the same cells, six or more weeks after initial
administration.82 Although these were patients with multiply relapsed lymphomas and
extensive chemotherapy exposure, none received lymphodepleting chemotherapy before
adoptive T cell therapy. If a primary immune response had resulted from the initial exposure
to the CAR-T cells, a secondary response should have quickly eliminated the reinfused cells.
4.4. Improving factors extrinsic to T cells
Besides focusing on improving the intrinsic properties of modified T cells used for cancer
therapy, there are a few approaches that that may be helpful at prolonging their survival and
that do not necessarily depend on gene transfer. First, it is now well established that
lymphocytic expansion is subjected to homeostatic mechanisms that control the total
numbers of T cells.83 Therefore, it has become apparent that a certain degree of
lymphopenia will facilitate expansion of adoptively transferred T cells. Whereas this will
always be the case after hematopoietic stem cell transplantation (given the nature of the
conditioning regimens, which are myeloablative and lymphodepleting), cancer patients who
have been off chemotherapy for long periods of time may have a full lymphocytic
compartment. In this case, induction of lymphodepletion prior to infusion of CAR-T cells
may facilitate their expansion after infusion. Presumably, this occurs because lymphopenia
creates space for the oncoming adoptively transferred cells and induces their homeostatic
expansion. This effect is mediated, on one hand, through chemotherapeutic ablation of
endogenous regulatory T cells, which normally secrete inhibitory cytokines, such as TGF-β
and interleukin (IL)-10, that limit effector T cell expansion.84 On the other hand, T-cell
growth homeostatic cytokines, such as IL-7 and IL-15, which ordinarily exist in limiting
amounts, may become readily available due to less competition and increased production by
lymphopoetic stromal cells.85 The approach has been previously used and encouraging
results have been seen,86–88 although it is difficult to tease out the antitumor effects
mediated by the T cells from those of the lymphodepleting drug (which is usually a
chemotherapeutic agent that may have intrinsic antitumor activity).
Furthermore, as previously described, provision of T-cell growth factors, such as IL-2,41
IL-789 or IL-15,90 may improve survival of CAR-T cells, especially if these cells are
modified to improve the responsiveness to these cytokines.91 Finally, the levels of
expression of some TAA may be amenable to modulation using drugs that exert epigenetic
effects, such as hypomethylating agents and histone deacetylase (HDAC) inhibitors.
Increasing the density of surface antigens may facilitate engagement of CARs and,
secondarily, activation and proliferation of the cells bearing those receptors. For instance, in
a murine model of melanoma, administration of an HDAC inhibitor was shown to increase
MHC and TAA expression by tumor cells, presumably by upregulating their gene
expression.92 This, together with beneficial effects on the adoptively transferred cells
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(mediated by a decrease in competing endogenous lymphocytes also brought about by the
drug), led to enhanced tumor immunotherapy.
5. Effector mechanisms
5.1. Killing
Apart from a suggestion that CARs containing a ζ transmembrane domain can form a
complex with the endogenous TCR,93 which in turn may drive optimal T cell activation,
little is known about the details of the initial activation of CARs. The common assumption is
that dimerization or multimerization of the receptors resulting from binding target antigen
epitopes brings together their cytoplasmatic signaling domains, which then become targets
for intracellular kinases, such as Lck.72 Phosphorylation of the immunoreceptor tyrosine-
based activation motives (ITAM) contained in the signaling portion of the CARs then recruit
adapter molecules, such as ZAP-70, which in turn stimulate downstream pathways that lead
to activation of the transduced cells. Depending on the exact nature of the transduced cell,
this leads to release of cytotoxic molecules (such as perforin or granzymes), expression of
proapoptotic ligands (such as Fas ligand – FasL, and tumor necrosis factor-related apotosis
inducing ligand – TRAIL) or secretion of proinflammatory cytokines (such as IL-2, IFN-γ
and TNF-α). As a consequence, tumor cells can be eliminated directly by the CAR-T cells or
other immune cells can be recruited to the tumor microenvironment, which usually is hostile
to effector T cells because of the presence of immunosuppressive cells (such as regulatory T
cells, stromal cells and myeloid derived stromal cells) and inhibitory cytokines secreted by
them (such as TGF-β and IL-10).6 As discussed above, incorporation of additional signaling
domains may be able to bypass some of the stimulatory events or amplify these effects.
5.2. Improving function
A few additional strategies may be important for optimizing the effector function of CAR-
modified T cells. One aspect that has received some attention is that of modulating the
affinity of the CAR for its corresponding antigen. Although it would seem beneficial to
ensure increased affinity, this may not be necessarily the case.15 On one hand, the binding
affinity of TCRs is usually lower than that of antibodies and so having high affinity may not
be needed to trigger activation. On the other hand, having lower affinity for the antigen may
target preferentially tissues that have higher density of tumor associated antigens (sparing
normal tissues), may facilitate disengagement of the CAR and allow the recycling of the T
cells, and may decrease inhibition of these cells by soluble antigen. It has been shown, for
instance, that the activation threshold for an HER2-specific CAR is inversely correlated with
the affinity of the CAR binding domain, such that T cells expressing a lower affinity CAR
are activated exclusively by cells with high amounts of HER2, in contrast to cells with a
high affinity CAR, which are activated against cells displaying a wide range of HER2 levels.
However, the maximum level of cellular activation achieved is comparable in either setting
and independent of the binding affinity.94 Therefore, higher affinity CARs do not
necessarily induce a more potent activation of T cells than low affinity counterparts and may
in fact be associated with less discrimination between target cells with high or low target
antigen expression levels. Fine tuning the affinity of the CAR may thus improve the efficacy
of CAR-bearing cells.
Moreover, successful effector function requires the CAR-expressing T cell to be able to
travel and localize to the targeted tumor sites. This homing process depends on the
activation of receptors in the T cells by chemokines released by the tumor. For instance,
forcing expression of chemokine receptors, such as CCR4, which may not be adequately
upregulated during in vitro activation, may thus improve migration of the CAR-expressing
cells.95
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Finally, several tumors are intrinsically immunosuppressive because they secrete inhibitory
cytokines or because they actively recruit inhibitory cells through, for example, production
of CCL2, a chemokine that promotes trafficking of regulatory T cells to tumors.96 To protect
CAR-expressing cells from these effects, they can be engineered to express dominant
negative receptors for inhibitory cytokines, to display a higher density of receptors for
activating cytokines or to secrete stimulating cytokines in an autocrine fashion.
For instance, EBV-positive Hodgkin and non-Hodgkin lymphoma cells secrete large
amounts of TGF-β, with suppressive activity over effector T cells that could potentially
recognize and destroy these tumors. The expression of a dominant negative TGF-β receptor
(TGFβR) on EBV-specific CTLs inactivates the native TGFβR and blocks the inhibitory
activity of TGF-β over those cells. TGF-β-resistant CTLs have a functional advantage over
unmodified CTLs in the presence of TGF-β-secreting EBV-positive lymphomas and have
enhanced antitumor activity.97 Furthermore, it is known that expression of the IL-7 receptor
alpha chain (IL-7Rα) is lost during activation of CTLs, precluding their response to this
homeostatic cytokine. By genetically modifying CTLs to re-express IL-7Rα, response of
these cells to IL-7 can be restored, without apparent modification of their antigen specificity
or dependency.91 Finally, transgenic expression of IL-2 and IL-15 in EBV-specific CTLs
has been seen to increase the expansion of these CTLs (both in vitro and in vivo in a SCID
mouse model) and to enhance their antitumor activity, with their proliferation remaining
strictly antigen dependent. Because, for example, systemic administration of IL-2 is
associated with toxicity and can cause expansion of unwanted cells, including regulatory T
cells, that strategy may overcome these problems.98
6. Targeted antigens
The great majority of the work with CARs has been done in vitro or in animal models. At
this point, however, a large number of clinical trials building on this large body of
preclinical data is being conducted and their results are beginning to be published. Table I
summarizes many of the TAAs that have been targeted so far and provides references
detailing the preclinical and, when available, clinical studies. While most studies are geared
toward treating malignancies, a few studies have addressed chronic viral infections, such as
HIV,18 and autoimmune disorders.99 Because CAR-expressing cells infused with
therapeutic intent get quickly diluted in circulation, their direct detection in peripheral blood
is usually challenging. To improve sensitivity, quantitative real time polymerase chain
reaction (PCR) techniques for amplification of the transgene are commonly used to
document their presence and quantify their expansion.
6.1. Summary of clinical experience in cancer patients
As in most phase I trials, the clinical studies published (Table II) have mostly included
patients whose disease is unresponsive to standard therapies, with many of them having
received multiple chemotherapy regimens before being given adoptive T-cell therapy. In one
of the first published clinical studies in cancer, 3 patients were treated with retrovirally
transduced T cells bearing a CAR specific for carbonic anhydrase IX, a membrane antigen
expressed by renal cell carcinoma cells, and low-dose IL-2. CAR-bearing T cells were
transiently detected up to 7 weeks after infusion and no tumor responses were observed. All
patients developed low levels of anti-idiotype antibody and evidence of liver toxicity, the
latter thought to be caused by off-target effects related to the expression of CA IX in biliary
ducts.100 These data have been recently updated (Table II).81
A study employing a CAR directed at the alpha-folate receptor (αFR) expressed in ovarian
carcinoma demonstrated by PCR analysis that gene-modified T cells were present in the
circulation in large numbers for the first 2 days after transfer, but that they quickly declined
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to almost undetectable 1 month later in most of the 14 patients treated. T cells were
transduced via a retrovirus and activated with OKT3 or with allogeneic cells. An inhibitory
factor, most likely an antibody, developed in half of 6 patients tested over the period of
treatment, which significantly reduced the ability of gene-modified T cells to respond
against tumor cells.101
T cells modified with a CAR specific for CD171, a cell adhesion molecule that is
overexpressed in metastatic neuroblastoma and that may be involved in progression of the
disease, were used for treatment of neuroblastoma patients in another CAR clinical trial.
These cells were subjected to polyclonal activation, electroporation with a plasmid encoding
the CAR and a marker, and hygromycin selection. No overt toxicities to tissues known to
express CD171, such as the central nervous system, were observed. The persistence of T
cells by PCR was shorter than 1 week in most patients with bulky disease, but up to 6 weeks
in a patient with smaller disease burden.39 In another clinical trial in neuroblastoma, 11
patients were treated with identical numbers of polyclonal OKT3-activated T cells and
EBV-specific LCL-stimulated T cells, with both cell populations expressing a GD2-
ganglioside-specific CAR. No toxicities were observed and T-cell infusion was associated
with tumor regression or necrosis in half of the subjects tested. The modified EBV-specific
T cells demonstrated longer survival, of up to 6 weeks.40
Several trials addressing treatment of lymphoid malignancies have been reported recently. In
one of the studies, 7 patients with follicular or mantle cell lymphomas received CD20-
specific CAR-modified T-cell infusions, with minimal toxicities. T cells were subjected to
polyclonal activation, plasmid electroporation and neomycin selection. The modified T cells
persisted in vivo up to 9 weeks in patients who also received low-dose subcutaneous IL-2
injections. Two patients had continued complete response, one achieved partial response,
and 4 had stable disease.41 In another study, 2 patients with recurrent diffuse large B cell
lymphoma were treated with cloned CD8+ T cells expressing a CD20-specific CAR (and
neomycin resistance) after autologous hematopoietic stem cell transplantation, and 2 patients
with refractory follicular lymphoma were treated with polyclonally activated T cells bearing
a CD19-specific CAR (and hygromycin resistance) and low-dose IL-2. Neither clinical
responses nor overt toxicities were observed. Detection of transferred T cells by PCR was
shorter than 7 days. Cellular antitransgene immune rejection responses were noted in 2
patients.38 Another recent report describes a patient with advanced follicular lymphoma
treated with a preparative chemotherapy regimen followed by autologous T cells retrovirally
modified to express a CD19-specific CAR. The patient's tumor underwent significant partial
regression and B cells were absent from circulation for at least 39 weeks after T-cell
infusion, despite recovery of other blood cell counts. The CD19-CAR transgene was
detected in the peripheral blood up to 27 weeks after infusion.102
Finally, results of a phase I trial in which subjects with refractory/relapsed B cell
lymphomas were simultaneously infused with two autologous T cell products, both
expressing a CD19-specific CAR but with one CAR encoding both CD28 and ζ
endodomains while other including only the ζ endodomain, are now available. This strategy
allowed direct measurement of the consequences of adding a CD28 co-stimulatory
endodomain to CAR-redirected T cells in the same subject and established that T cells
bearing a CAR that contains the CD28 endodomain have enhanced in vivo proliferation and
survival compared to T cells expressing a CAR lacking CD28. Clinical responses were
limited, with two patients having transient stable disease and four showing progression of
disease.82
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One of the concerns with any technique that causes permanent genetic changes is that of
insertional mutagenesis, especially when there is little to no control over the sites of
integration. Although these fears have materialized in studies involving genetic modification
of hematopoietic stem cells, in which some children with severe combined
immunodeficiency (SCID) who were treated with common gamma-chain receptor genes
developed leukemia,103 this has not been seen in any of the preclinical and clinical studies
reported so far. That CAR-based gene transfer targets differentiated T cells, which have a
lower risk of malignant transformation, instead of hematopoietic stem cells, and that it
delivers transgenes whose stimulation is antigen driven, so that positive selection would
occur only in the presence of the target antigen, and whose signal transduction augments
committed cytotoxic effector cell function, could explain why this has not been a problem so
far. Furthermore, at least in a model in which murine T cells were retrovirally transduced
and adoptively transferred into congenic mice, there was no excess tumor incidence
compared to controls and none of the tumors observed were of donor T-cell origin.104
7.2. Off-target effects
A more significant concern has been potential off-target effects of the CAR-modified T
cells. Most antigens targeted by CARs are not tumor “specific”, but simply tumor
“associated”. This means that even though tumors may display higher densities of these
antigens, they are shared with normal tissues in the body. While some of those tissues may
be shielded from immune attack by physiological barriers, such as testes, many are not. In
some instances, bystander attack of normal tissues may be acceptable, as would be the case
with the destruction of normal B cells by CARs targeting CD19 or CD20, provided that the
malignancy being treated is controlled by the modified T cells. In other cases, however, the
implications are more serious. For instance, as described above, CA IX is expressed both in
renal cell carcinoma and the biliary tree, which may explain the observation that patients
treated with T cells expressing a CAR targeting that antigen developed significant liver
toxicity.100 Furthermore, a recently reported fatal adverse event in a trial employing a
HER2-specific CAR for treatment of metastatic colorectal cancer, in which a patient
developed acute respiratory failure, is thought to be related to low level expression of HER2
in the pulmonary parenchyma or vasculature.53
Identical problems have been observed with transgenic native TCRs. In a trial of melanoma
patients with T cells expressing TCRs against MART-1 or gp100 (antigens expressed by
melanoma and pigmented epithelia), several patients experienced transient skin rash, uveitis
or hearing loss, thought to be due to cytotoxic effects against normal melanocytes.8 In
another protocol using CEA-specific (an antigen expressed by colorectal cancer but also, in
lower levels, by normal colonic mucosa) transgenic TCRs, all three patients treated
developed dose limiting transient inflammatory colitis.105
7.3. Systemic inflammatory reaction, cytokine storm and tumor lysis syndrome
As with any therapy achieving significant tumor cell destruction, adoptive CAR-T cell
therapy can in theory lead to release into circulation of nucleic acid catabolites (including
urates and phosphates) and intracellular ions (mainly potassium), a condition known as
tumor lysis syndrome. In parallel, massive cell activation resulting from engagement of
CARs by tumor antigens could result in release of significant amounts of proinflammatory
cytokines into circulation, such as IFN-γ and TNF-α, a situation that has been referred to as
cytokine storm. These syndromes are life threatening and, therefore, close monitoring of
patients receiving these cells is required.
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Of note, a patient with bulky chronic lymphocytic leukemia, treated with cyclophosphamide
followed 2 days after by autologous T cells retrovirally transduced with a second generation
CD19-specific CAR, developed a fatal syndrome of hypotension, dyspnea, renal failure and
fever (Table II). An autopsy failed to reveal an obvious cause of death and sepsis was
thought to be the most likely precipitating factor, but the possibility that a
cyclophosphamide-induced “cytokine storm” that may have enhanced the in vivo activation
of modified T cells was also considered, as elevated cytokine levels were seen before the T-
cell infusion.106
7.4. Safety mechanisms
In some circumstances, it may be possible to identify alternative, more restricted tumor
antigens. An example of this is targeting the kappa107 or lambda light chains, a strategy
which would spare B cells expressing the alternative light chain. Most often, however, the
introduction of a safety mechanism allowing quick, on-demand elimination of gene
modified T cells should any untoward effects occur is desirable. Several inducible suicide
systems, which could be encoded in cis with the CAR gene, have been described.108
Strategies involving nucleoside analogues, such as those combining Herpes Simplex Virus
thymidine kinase (HSV-tk) with ganciclovir (GCV) and bacterial or yeast cytosine
deaminase (CD) with 5-fluoro-cytosine (5-FC) have been used successfully in some cases,
especially as a way to eliminate alloreactive T cells infused as part of a hematopoietic stem
cell transplant.109 A drawback of these systems is that they are cell-cycle dependent and
unlikely to be effective in non dividing cells. Additionally, the prodrugs required for suicide
may themselves have therapeutic uses that are therefore excluded (e.g. GCV), or may be
toxic (e.g. 5-FC). Also, nonhuman enzymatic systems, such as HSV-tk and CD, carry a high
risk of destructive immune responses against transduced cells.
An inducible caspase-9 (iCasp9) system, which addresses some of the problems of existing
approaches, has also been developed. This engineered protein can be activated using a
specific chemical inducer of dimerization (CID), a functionally identical analogue of which
(AP1903) has been safely tested in a phase I study in humans. The iCasp9 suicide gene is of
human origin, and thus should be less likely to induce unwanted immune responses.
Transduction of lymphocytes by this gene construct is stable and the cells are quickly and
specifically eliminated less than 24 hours after exposure to CID.110 It has recently been
shown that this approach can also be extended to other cell types, including post-mitotic
tissues.108 All this suggests that an inducible suicide system could be used for increased
safety of CAR-modified T cells.
8. Conclusion
CARs endow T cells with MHC-unrestricted ability to recognize cellular surface antigens,
freeing antigen recognition from HLA restriction and thus breaking one of the barriers to
more widespread application of cellular therapy. Similar to treatment strategies employing
monoclonal antibodies, T cells expressing CARs are highly targeted, but additionally offer
the potential benefits of active trafficking to tumor sites, in vivo expansion and long-term
persistence. Furthermore, gene transfer allows the introduction of countermeasures to tumor
immune evasion and of safety mechanisms. Although CAR-modified T cells have been used
in several clinical trials, the benefits observed so far have been modest. Incorporation of
more potent costimulatory domains into the CAR-molecule, better gene transfer methods,
transduction of specific memory populations, infusion of the modified T cells into a
lymphodepleted host and provision of T-cell-specific cytokines are expected to improve
these results, by enhancing the activation of the engineered T cells and prolonging their
persistence in vivo. As we learn more about the mechanisms responsible for immune
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activation and generation of memory, CAR-modified T cells will likely play an increasing
role in cellular therapy of cancer, chronic infections and autoimmune disorders.
9. Expert opinion
The long and winding road of immunotherapy has recently led us to some successes. CAR-
based technology is a major step forward towards off-the-shelf cellular therapy. Although
still requiring patient-specific (autologous or HLA-matched allogeneic) lymphocytes, these
cells can be modified to express an identical antigen receptor regardless of the HLA context,
meaning that each CAR is truly universal.
Improved gene transfer methods, better understanding of the cellular processes involved in T
cell activation and memory, and superior design of CARs to contain optimal activation
domains have allowed this strategy to be successfully brought to the clinic. Countermeasures
to tumor evasion mechanisms, such as rendering CAR-modified T cells resistant to
inhibitory cytokines, and enhancement of tumor trafficking, such as the coexpression of
effective homing receptors, will broaden the range of tumors that can be treated using this
approach. A tremendous body of knowledge will be available to us in the coming years as
many trials complete accrual.
Beyond these scientific developments, recent technical improvements in cell processing,
including automation and better culture systems, will make production of the modified cells
simpler and faster, allowing the use of these therapies outside the limited number of centers
where they can currently be administered. In parallel, these technical advances will drive
down the costs of production, which together with the low toxicity of this approach will
translate into a vastly favorable cost/benefit ratio when compared to conventional or targeted
chemotherapy drugs.
While it is hard to imagine that, in the near future, cellular immunotherapy alone will be
able to cure established cancers (the ultimate goal of the field), there is increasing
expectation that — like monoclonal antibodies — it will come to play an increasing role in a
multidisciplinary approach to these diseases. The last decades have shown us that, with few
exceptions, no single drug or therapeutic modality is able to cure advanced neoplasms.
Ultimate control and eradication of cancer will likely require a combination approach that
includes immunotherapy. The numerous ongoing clinical trials will allow us to gather
information regarding the best approaches to achieve this goal.
List of abbreviations
5-FC 5-Fluoro-Cytosine
APC Antigen Presenting Cell
CA IX Carbonic Anhydrase 9
CAR Chimeric Antigen Receptor
CD Cytosine Deaminase
CID Chemical Inducer of Dimerization
CTL Cytotoxic T Lymphocyte
DLI Donor Lymphocyte Infusion
EBV Epstein-Barr Virus
Fab Fragment, antigen binding
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HIV Human Immunodeficiency Virus
HLA Human Leukocyte Antigen




ITAM Immunoreceptor Tyrosine-based Activation Motives
LCL Lymphoblastoid Cell Line
mAb monoclonal Antibody
MHC Major Histocompatibility Complex
NK Natural Killer
PBMC Peripheral Blood Mononuclear Cells
PCR Polymerase Chain Reaction
PTLD Post-Transplant Lymphoproliferative Disorder
RCR Replication Competent Retrovirus
scFv single-chain Fragment variable
SCID Severe Combined ImmunoDeficiency
TAA Tumor-Associated Antigen
TGF Transforming Growth Factor
TNF Tumor Necrosis Factor
ZAP-70 Zeta-chain-Associated Protein kinase 70
αFR Alpha Folate Receptor
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Figure 1. The basic structure of a monoclonal antibody (mAb)-derived chimeric antigen receptor
(CAR)
The most common CARs combine the extracellular antigen recognition site of a mAb and
the intracellular domains of a T cell receptor complex (TCR) molecule, such as the ζ-chain.
Clustering of CARs induced by antigen binding is thought to be responsible for initiating
signal transduction that leads to T-cell activation and killing of the cells expressing the
target antigen.
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Figure 2. First versus second generation CARs
First generation CARs include a single stimulatory domain. Because most tumors do not
express costimulatory molecules (“signal 2”), T cells are incompletely activated even when
the CAR is engaged by the target antigen. Second generation CARs contain one additional
costimulatory endodomain, which is thought to improve T cell activation and proliferation,
and thus promote better killing of the target tumor cells.
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Figure 3. Retroviral transduction of T cells and expansion of CAR-expressing T cells
T cells are activated from the patient’s peripheral blood mononuclear cells (PBMC) by
stimulation with anti-CD3 antibody (OKT3) and these activated T cells are expanded with
interleukin 2 (IL-2) and transduced with a replication incompetent retrovirus encoding the
CAR. Further expansion in IL-2-containing medium is done until sufficient numbers for
clinical application are reached.
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Figure 4. Epstein-Barr Virus (EBV) and tumor bispecific cytotoxic T lymphocytes (CTLs)
Unlike most tumor cells (including malignant lymphocytes), EBV-transformed cells not
only express specific antigens but also high levels of many different costimulatory
molecules, including CD40L, CD80 and CD86. Because they express both class I and class
II human leukocyte antigen (HLA) molecules, they can present viral epitopes that will
stimulate both CD8 and CD4 virus-specific cells, favoring the cognate interactions between
T cell subsets that are critical for optimal and sustained immune responses. CTLs with
native receptor (αβ-TCR) specificity directed to EBV receive physiological costimulation in
vivo during their encounters with persistent viral antigens on professional antigen presenting
cells. If these EBV-specific CTLs are modified to co-express a CAR directed to a tumor
associated antigen, they will obtain physiologic costimulatory signals following engagement
of their native receptors, which in turn will enhance their survival and their CAR-mediated
anti-tumor activity.
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Table I
Examples of tumor associated antigens that have been targeted with CARs.
Tumors/Antigens Description Trials
Gastrointestinal
  EGP2/EpCam27, 111 Epithelial glycoprotein 2/Epithelial cell adhesion molecule No
  EGP40112 Epithelial glycoprotein 40 No
  TAG72/CA72-419, 113 Tumor associated glycoprotein 72/Cancer antigen 72-4 No
Glioblastoma
  IL13Rα216 Interleukin 13 receptor alpha-2 subunit Yes*
Kidney
  G250/MN/CA IX114 Carbonic anhydrase IX Yes100
Lymphoid malignancies
  CD1973, 75, 115–117 – Yes38, 82, 102, 106
  CD2041, 47, 52, 118 Membrane-spanning 4-domains subfamily A member 1 Yes38, 41, 118
  CD2223 Sialic acid-binding Ig-like lectin 2 No
  CD3076, 119 Tumor necrosis factor receptor superfamily member 8 Yes*
  κ107 Kappa light chain Yes*
Melanoma
  GD3120 GD3-Ganglioside No
  HLA-A1+MAGE-1121, 122 Human leukocyte antigen A1 + Melanoma antigen 1 No
Neuroblastoma
  CD171123 L1 cell adhesion molecule Yes39
  GD2124 GD2-Ganglioside Yes40
  NCAM36 Neural cell adhesion molecule No
Ovary (mainly)
  FBP/αFR26, 74 Folate binding protein/alpha folate receptor Yes101
  Le(Y)125, 126 Lewis-Y antigen No
  MUC124 Mucin 1 No
Prostate
  PSCA127 Prostate stem cell antigen No
  PSMA45, 128 Prostate-specific membrane antigen Yes*
Rhabdomyosarcoma
  FAR129 Fetal acetylcholine receptor No
Several solid tumors
  CEA28, 130–132 Carcinoembryonic antigen Yes*
  ERBB2/HER248, 133–137 Avian erythroblastic leukemia viral oncogene homolog 2/Human epidermal growth factor
receptor 2
Yes53
  ERBB3+ERBB417, 138 Avian erythroblastic leukemia viral oncogene homolog 3 + 4 No
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Tumors/Antigens Description Trials
  Mesothelin49 – No
Various tumors
  CD44v6139 Hyaluronate receptor variant 6 No




Clinical trials listed on http://www.clinicaltrials.gov, but whose results have not been published.
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